161 related articles for article (PubMed ID: 35377434)
1. Pharmacokinetics and Safety of Bedaquiline in Human Immunodeficiency Virus (HIV)-Positive and Negative Older Children and Adolescents With Rifampicin-Resistant Tuberculosis.
Hughes JA; Solans BP; Draper HR; Schaaf HS; Winckler JL; van der Laan L; Radtke KK; Fourie B; Wiesner L; Hesseling AC; Savic RM; Garcia-Prats AJ
Clin Infect Dis; 2022 Nov; 75(10):1772-1780. PubMed ID: 35377434
[TBL] [Abstract][Full Text] [Related]
2. Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety.
Gao JT; Du J; Wu GH; Pei Y; Gao MQ; Martinez L; Fan L; Chen W; Xie L; Chen Y; Wang H; Jin L; Li GB; Zong PL; Xiong Y; Wu QH; Li MW; Yan XF; Miao YF; Cai QS; Li XJ; Bai DP; Geng SJ; Yang GL; Tang PJ; Zeng Y; Chen XH; Li TX; Cai C; Zhou Y; Zhuo M; Wang JY; Guan WL; Xu L; Shi JC; Shu W; Cheng LL; Teng F; Ning YJ; Xie SH; Sun YX; Zhang LJ; Liu YH
Infect Dis Poverty; 2021 Mar; 10(1):32. PubMed ID: 33736710
[TBL] [Abstract][Full Text] [Related]
3. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
Centers for Disease Control and Prevention
MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and Cardiac Safety of Bedaquiline-Based Therapy for Drug-Resistant Tuberculosis: A Prospective Cohort Study.
Brust JCM; Gandhi NR; Wasserman S; Maartens G; Omar SV; Ismail NA; Campbell A; Joseph L; Hahn A; Allana S; Hernandez-Romieu AC; Zhang C; Mlisana K; Viljoen CA; Zalta B; Ebrahim I; Franczek M; Master I; Ramangoaela L; Te Riele J; Meintjes G
Clin Infect Dis; 2021 Dec; 73(11):2083-2092. PubMed ID: 33882121
[TBL] [Abstract][Full Text] [Related]
5. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
[TBL] [Abstract][Full Text] [Related]
6. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
Worley MV; Estrada SJ
Pharmacotherapy; 2014 Nov; 34(11):1187-97. PubMed ID: 25203970
[TBL] [Abstract][Full Text] [Related]
7. Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis.
Brill MJ; Svensson EM; Pandie M; Maartens G; Karlsson MO
Int J Antimicrob Agents; 2017 Feb; 49(2):212-217. PubMed ID: 28038962
[TBL] [Abstract][Full Text] [Related]
8. Twenty-four-week interim outcomes of bedaquiline-containing regimens in treatment of adolescents with rifampicin-resistant tuberculosis: A retrospective cohort study in China.
Wu HY; Tian Y; Wang XD; Sun JS; Fan LC; Chen MX; Li R; Chen Y
J Paediatr Child Health; 2022 Jan; 58(1):116-121. PubMed ID: 34323328
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies.
Garcia-Prats AJ; Schaaf HS; Draper HR; Garcia-Cremades M; Winckler J; Wiesner L; Hesseling AC; Savic RM
PLoS Med; 2019 Apr; 16(4):e1002789. PubMed ID: 31039153
[TBL] [Abstract][Full Text] [Related]
10. Effects of Bedaquiline Combined with Fluoroquinolone and/or Clofazimine on QT Interval in Patients with Multidrug-Resistant Tuberculosis: a Retrospective Study.
Li R; Ma JB; Yang H; Yang H; Yang XJ; Wu YQ; Ren F
Microbiol Spectr; 2023 Aug; 11(4):e0104823. PubMed ID: 37310268
[TBL] [Abstract][Full Text] [Related]
11. Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
Svensson EM; Dooley KE; Karlsson MO
Antimicrob Agents Chemother; 2014 Nov; 58(11):6406-12. PubMed ID: 25114140
[TBL] [Abstract][Full Text] [Related]
12. Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children.
Radtke KK; Hesseling AC; Winckler JL; Draper HR; Solans BP; Thee S; Wiesner L; van der Laan LE; Fourie B; Nielsen J; Schaaf HS; Savic RM; Garcia-Prats AJ
Clin Infect Dis; 2022 Apr; 74(8):1372-1381. PubMed ID: 34286843
[TBL] [Abstract][Full Text] [Related]
13. Safety and Effectiveness of an All-Oral, Bedaquiline-Based, Shorter Treatment Regimen for Rifampicin-Resistant Tuberculosis in High Human Immunodeficiency Virus (HIV) Burden Rural South Africa: A Retrospective Cohort Analysis.
Tack I; Dumicho A; Ohler L; Shigayeva A; Bulti AB; White K; Mbatha M; Furin J; Isaakidis P
Clin Infect Dis; 2021 Nov; 73(9):e3563-e3571. PubMed ID: 33372989
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics of Bedaquiline and Metabolite M2 in Patients With Drug-Resistant Tuberculosis: The Effect of Time-Varying Weight and Albumin.
Svensson EM; Dosne AG; Karlsson MO
CPT Pharmacometrics Syst Pharmacol; 2016 Dec; 5(12):682-691. PubMed ID: 27863179
[TBL] [Abstract][Full Text] [Related]
15. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
Dooley KE; Rosenkranz SL; Conradie F; Moran L; Hafner R; von Groote-Bidlingmaier F; Lama JR; Shenje J; De Los Rios J; Comins K; Morganroth J; Diacon AH; Cramer YS; Donahue K; Maartens G;
Lancet Infect Dis; 2021 Jul; 21(7):975-983. PubMed ID: 33587897
[TBL] [Abstract][Full Text] [Related]
16. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis.
Chahine EB; Karaoui LR; Mansour H
Ann Pharmacother; 2014 Jan; 48(1):107-15. PubMed ID: 24259600
[TBL] [Abstract][Full Text] [Related]
17. Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis.
Achar J; Hewison C; Cavalheiro AP; Skrahina A; Cajazeiro J; Nargiza P; Herboczek K; Rajabov AS; Hughes J; Ferlazzo G; Seddon JA; du Cros P
Emerg Infect Dis; 2017 Oct; 23(10):1711-3. PubMed ID: 28758889
[TBL] [Abstract][Full Text] [Related]
18. Adverse drug reactions in South African patients receiving bedaquiline-containing tuberculosis treatment: an evaluation of spontaneously reported cases.
Jones J; Mudaly V; Voget J; Naledi T; Maartens G; Cohen K
BMC Infect Dis; 2019 Jun; 19(1):544. PubMed ID: 31221100
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis.
Thee S; Garcia-Prats AJ; Draper HR; McIlleron HM; Wiesner L; Castel S; Schaaf HS; Hesseling AC
Clin Infect Dis; 2015 Feb; 60(4):549-56. PubMed ID: 25362206
[TBL] [Abstract][Full Text] [Related]
20. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.
Ndjeka N; Schnippel K; Master I; Meintjes G; Maartens G; Romero R; Padanilam X; Enwerem M; Chotoo S; Singh N; Hughes J; Variava E; Ferreira H; Te Riele J; Ismail N; Mohr E; Bantubani N; Conradie F
Eur Respir J; 2018 Dec; 52(6):. PubMed ID: 30361246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
